purdue sackler opioid oxycontin crisis bankruptcy doj lobbying accountability revolving-door dark-money pharma fda
related: PhRMA Johnson & Johnson AbbVie Pfizer Eli Lilly
Who They Are
Purdue Pharma LP and the Sackler family. The privately held pharmaceutical company that manufactured OxyContin — the drug most responsible for igniting the American opioid epidemic that has killed 600,000+ Americans since 1999. The Sackler family, which owned Purdue Pharma, extracted over $10 billion from the company between 2008 and 2018 before filing for bankruptcy in 2019 to shield remaining assets from litigation. Three generations of Sacklers directed the company’s aggressive marketing of OxyContin while denying its addictive potential.
The Sackler family fortune was built on pharmaceutical marketing innovation. Arthur Sackler (d. 1987) pioneered direct-to-physician pharmaceutical advertising in the 1950s-60s through his agency, developing the playbook that his brothers Mortimer and Raymond would later apply to OxyContin. Forbes listed the Sacklers as the 19th richest family in America in 2016 with a $13 billion net worth — wealth derived almost entirely from opioid sales.
Purdue’s political operation was smaller than its industry peers in direct contributions but strategically targeted: the company focused lobbying on the FDA (which approved OxyContin with a misleading label), state medical boards (which set prescribing guidelines), pain management professional organizations (which Purdue funded to promote opioid prescribing), and attorneys general (who held enforcement power over pharmaceutical marketing). OpenSecrets data shows Purdue spent $860K on lobbying in 2020, peaked at $1.12M in 2018, and continued spending $400K annually through 2024 — even in bankruptcy. The revolving door rate is extraordinary: 87.5% of Purdue’s lobbyists in 2023 (7 of 8) previously held government jobs.
- OpenSecrets: Purdue Pharma organizational profile (Tier 1)
- OpenSecrets: Purdue Pharma lobbying profile (Tier 1)
What They Want
Historically: expanded OxyContin prescribing, FDA-approved labeling that minimized addiction risk, opposition to prescription drug monitoring programs (PDMPs), suppression of abuse data, and protection from criminal prosecution for the Sackler family personally. During and after bankruptcy: favorable settlement terms, Sackler family immunity from civil litigation, preservation of offshore wealth, and continuation of Purdue’s international opioid business through Mundipharma (the Sackler-owned international affiliate that continued marketing opioids overseas while the U.S. operations faced litigation).
Who They Fund
Purdue’s political spending operated on two tracks: the company PAC for direct federal contributions, and the Sackler family’s personal donations for broader political influence.
Purdue Pharma PAC contributions were modest ($1-2M per cycle at peak) but targeted at members of Congress overseeing DOJ, DHS, and pharmaceutical regulation. The PAC contributed almost exclusively to Republicans in the 2018 cycle, with Rep. G.K. Butterfield (D-NC) the only Democrat receiving contributions.
Sackler family personal donations were more substantial and bipartisan:
- Richard Sackler (former chairman/president): $170,250+ to predominantly Republican causes — Mitt Romney, RNC, NRSC, NRCC
- Mortimer D.A. Sackler (board member): $439,099, almost entirely Republican
- Jonathan Sackler: $284,895, favoring Democrats — including Sen. Chris Murphy (D-CT), Purdue’s home-state senator
Attorneys General — the critical investment: Purdue donated $125,000 to the Republican Attorneys General Association (RAGA) in the 2018 cycle and over $500,000 to RAGA in 2016. This is the vault’s clearest case of strategic donation targeting: attorneys general are the officials with direct enforcement power over pharmaceutical marketing practices. Purdue invested in the organization that elects the people who decide whether to prosecute companies like Purdue.
Money
Purdue’s RAGA donations represent the most direct form of regulatory capture in the vault: the company donated $625,000+ to the organization that elects state attorneys general — the very officials tasked with investigating and prosecuting pharmaceutical marketing fraud. While individual AG races received smaller amounts, the organizational investment bought influence over the entire Republican AG pipeline. Multiple Republican AGs initially declined to join opioid lawsuits against Purdue.
What They’ve Gotten
The FDA Label (1995) — The Foundational Crime
Purdue Pharma’s most consequential political achievement was the 1995 FDA approval of OxyContin with labeling that stated the drug’s extended-release formulation was “believed to reduce” abuse potential. This claim had no scientific basis — it enabled Purdue to market OxyContin as safer than other opioids to physicians nationwide. The company then deployed 1,000+ sales representatives to push OxyContin for non-cancer chronic pain, a vast expansion of opioid prescribing.
The revolving door sealed the deal: Curtis Wright IV, the FDA medical officer who led the review and approved OxyContin’s label, resigned from the FDA and joined Purdue Pharma in 1998 as executive director of medical research. His first-year compensation was at least $379,000 — roughly three times his government salary. Wright had met with Purdue representatives in a hotel room near FDA offices during the review process and allowed the company to help draft portions of his medical officer’s review.
Contradiction
The FDA reviewer who approved OxyContin’s misleading “less addictive” label was hired by Purdue Pharma within three years, tripling his salary. The label he approved became the foundation of Purdue’s marketing campaign that contributed to 600,000+ American deaths. This is the revolving door as cause of death.
The 2007 Plea Deal — Accountability Theater
In May 2007, Purdue Frederick (Purdue’s holding company) and three executives pleaded guilty to felony and misdemeanor charges of misbranding OxyContin. The company paid $600 million in fines. Three executives — President Michael Friedman, Chief Legal Officer Howard Udell, and former Chief Medical Officer Paul Goldenheim — pleaded guilty to misdemeanor charges and paid a combined $34.5 million in personal fines. No executive served prison time. The Sackler family was not charged.
| Date | Event | Amount | Source |
|---|---|---|---|
| 1995-12 | FDA approves OxyContin with misleading label | — | FDA |
| 1996-01 | Purdue begins marketing OxyContin as less addictive | — | DOJ |
| 1998 | FDA reviewer Curtis Wright joins Purdue Pharma | $379K+ salary | ProPublica |
| 2007-05 | Purdue Frederick pleads guilty to misbranding | $600M fine | PBS/DOJ |
| 2007-05 | Three executives plead guilty to misdemeanors | $34.5M personal | PBS/DOJ |
| 2008-2018 | Sackler family extracts $10.4B from Purdue | $10.4B | CNN |
| 2019-09 | Purdue files for bankruptcy | — | NPR |
| 2020-11 | Purdue pleads guilty to three federal felonies | $8.3B settlement | HHS OIG |
| 2024-06 | Supreme Court rejects Sackler immunity deal | — | SCOTUS |
| 2025 | Revised $7.4B settlement reached | $6.5B Sackler share | NY AG |
Wealth Extraction While America Died (2008-2018)
Between 2008 and 2018 — the decade when opioid overdose deaths surged from 36,450 to 67,367 annually — the Sackler family withdrew $10.4 billion from Purdue Pharma, directing it into offshore trusts, holding companies, and asset protection structures. This was eight times more than the previous 13 years of withdrawals. The timing is not coincidental: the family accelerated extraction as litigation risk increased, moving wealth beyond the reach of American courts before filing for bankruptcy.
Money
The Sacklers extracted $10.4 billion from Purdue during the same decade that opioid deaths nearly doubled in America. The money went into offshore trusts and shell companies specifically designed to be unreachable by creditors — meaning the families of the dead. The bankruptcy filing was the final step: after extracting the wealth, Purdue filed for Chapter 11 to shield what remained. The structural lesson: American corporate and trust law allowed the Sacklers to profit from mass death, hide the profits offshore, then use bankruptcy to limit accountability — all while retaining personal wealth estimated at $10.8 billion.
The 2020 Federal Plea — $8.3 Billion in Uncollectable Fines
On November 24, 2020, Purdue Pharma pleaded guilty to three federal felonies: one count of conspiracy to defraud the United States and violate the Food, Drug, and Cosmetic Act, and two counts of conspiracy to violate the Federal Anti-Kickback Statute. The settlement totaled $8.3 billion — $3.544 billion in criminal fines, $2 billion in criminal forfeiture, and $2.8 billion in civil liability.
Purdue admitted it conspired to impede the DEA by misrepresenting its anti-diversion program while continuing to market opioids to 100+ healthcare providers it had reason to believe were diverting drugs. The company also admitted to paying kickbacks to electronic health records company Practice Fusion to generate OxyContin prescriptions.
The critical limitation: the $8.3 billion in fines were largely uncollectable from a bankrupt company. The Sackler family members did not admit criminal wrongdoing. No individual Sackler was charged.
The Supreme Court and the Immunity Question (2024-2025)
The Sacklers’ bankruptcy strategy centered on obtaining permanent immunity from civil lawsuits in exchange for contributing a fraction of their extracted wealth. The initial plan: $4.5 billion in Sackler contributions over time in exchange for a release from all opioid-related claims — permanently.
On June 27, 2024, the Supreme Court ruled 5-4 in Harrington v. Purdue Pharma L.P. that bankruptcy law does not authorize releasing claims against non-debtors (the Sacklers) without affected claimants’ consent. Justice Gorsuch’s majority opinion noted the Sacklers sought what amounted to a bankruptcy discharge without actually filing for bankruptcy or placing their assets on the table.
A revised settlement was reached in 2025: $7.4 billion total, with the Sackler family contributing up to $6.5 billion over 15 years. The settlement ends Sackler control of Purdue and their ability to sell opioids in the United States — but the family retains significant personal wealth and faces no criminal charges.
Class Analysis
The Purdue Pharma-Sackler case is the vault’s most extreme example of the privatize-profits-socialize-costs model in American corporate history. The family extracted $10+ billion from a product that killed 600,000+ Americans, used the profits to fund philanthropy that whitewashed their reputation (the Sackler name appeared on wings at the Met, the Louvre, and dozens of universities), then deployed corporate legal structures — bankruptcy, offshore trusts, asset protection vehicles — to limit accountability to a fraction of their wealth.
Analytical patterns present:
- Revolving Door (extreme): Curtis Wright’s FDA-to-Purdue pipeline is the vault’s most consequential single revolving door case — the regulator who approved the misleading label was hired by the company that used it to market a drug that killed hundreds of thousands. 87.5% of Purdue’s 2023 lobbyists are government alumni.
- Donor-Class Override: The $625,000+ in RAGA donations invested in the officials who decide whether to prosecute pharmaceutical companies. Multiple Republican AGs initially declined to join opioid litigation.
- Genuine Win + Structural Limit: The $7.4B settlement is a real recovery for victims — but it represents roughly 50-65% of the family’s extracted wealth, paid over 15 years, with no criminal charges against any Sackler. The family retains billions.
- Two-Audience Problem: The Sacklers presented themselves as philanthropists to cultural institutions while internally directing aggressive opioid marketing. Richard Sackler’s sealed testimony revealed he embraced plans to conceal OxyContin’s true strength from doctors.
Enemies / Opposition
State attorneys general (particularly Maura Healey of Massachusetts, who was first to name individual Sacklers in litigation), the Bankruptcy Abuse Prevention and Consumer Protection Act reform advocates, investigative journalists (Patrick Radden Keefe’s Empire of Pain, ProPublica’s Opioid Billionaires series), and opioid victim advocacy organizations including the National Alliance for Prescription Drug Abuse Prevention.
Connected Policy Areas
Drug pricing and FDA regulation, opioid prescribing guidelines, prescription drug monitoring programs, bankruptcy reform (the SACKLER Act would prohibit non-debtor releases in bankruptcy), pharmaceutical marketing regulation, Medicaid and Medicare opioid spending, state-level tort reform, and corporate criminal accountability.
Sources
- OpenSecrets: Purdue Pharma organizational profile (Tier 1)
- OpenSecrets: Purdue Pharma lobbying profile (Tier 1)
- HHS OIG: Purdue Pharma pleads guilty to fraud and kickback conspiracies (Tier 1)
- Supreme Court: Harrington v. Purdue Pharma L.P., 23-124 (2024) (Tier 1)
- GovInfo: House hearing — The Role of Purdue Pharma and the Sackler Family in the Opioid Epidemic (Tier 1)
- NY Attorney General: $7.4B settlement with Purdue Pharma and Sackler Family (Tier 1)
- OpenSecrets: Purdue Pharma and Sackler family political spending analysis (Tier 2)
- ProPublica: Sackler embraced plan to conceal OxyContin’s strength from doctors (Tier 2)
- CNN: Sackler family withdrew more than $10 billion from Purdue during opioid crisis (Tier 2)
- NPR: Sackler family’s ‘personal wealth’ offered in opioid deal (Tier 2)
- PBS NewsHour: OxyContin maker guilty of misleading public (2007) (Tier 2)
- Ballotpedia: Opioid crisis (Tier 3)
content-readiness:: developed